Top

Published in:

01-05-2016 | Original Article

Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV

Authors: K. M. Klassen, M. G. Kimlin, C. K. Fairley, S. Emery, P. H. Anderson, P. R. Ebeling, on behalf of the STEAL Study Group

Published in: Osteoporosis International | Issue 5/2016

Abstract

Summary

Rationale: To see if vitamin D and antiretroviral therapy are associated with bone mineral density (BMD) in people with HIV. Result: Lower hip BMD was associated with tenofovir (an antiretroviral medicine) in those with 25(OH)D ≥50 nmol/L. Significance: The relationship between antiretroviral therapy and hip BMD differs depending on vitamin D status.

Introduction

People with HIV have an increased risk of low BMD and fractures. Antiretroviral therapy contributes to this increased risk.

The aim of this study was to evaluate associations between vitamin D metabolites and antiretroviral therapy on BMD.

Methods

The simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine trial (STEAL) was an open-label, prospective randomised non-inferiority study that compared simplification of current nucleoside reverse transcriptase inhibitors (NRTIs) to fixed-dose combination tenofovir-emtricitabine (TDF-FTC) or abacavir-lamivudine. Serum 25(OH)D and 1,25(OH)₂D were measured in 160 individuals (90 receiving TDF-FTC, 70 receiving other NRTIs) at baseline from this study. Multivariable linear regression models were constructed to evaluate the covariates of 1,25(OH)₂D and BMD.

Results

Protease inhibitor use (p = 0.02) and higher body mass index (BMI) (p = 0.002) were associated with lower 1,25(OH)₂D levels in those with 25(OH)D <50 nmol/L. However, TDF-FTC use (p = 0.01) was associated with higher 1,25(OH)₂D levels, but only in those with 25(OH)D ≥50 nmol/L.

White ethnicity (p = 0.02) and lower BMI (p < 0.001) in those with 25(OH)D <50 nmol/L and with TDF-FTC use (p = 0.008) in those with 25(OH)D ≥50 nmol/L were associated with lower hip BMD. TDF-FTC use, higher serum calcium and serum βCTX, winter, and lower bone-specific alkaline phosphatase (BALP) and BMI were associated with lower lumbar spine BMD.

Conclusion

TDF-FTC use (versus non-TDF-FTC use) was associated with lower hip BMD, and this difference was more pronounced in those with 25(OH)D ≥50 nmol/L. Serum 25(OH)D <50 nmol/L was associated with lower hip BMD in all participants. Therefore, the associations between antiretroviral therapy and hip BMD differ depending on vitamin D status.

Brown T, Qaqish R (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20:2165–2174CrossRefPubMed

Mallon PW (2010) HIV and bone mineral density. Curr Opin Infect Dis 23:1–8CrossRefPubMed

Triant VA, Brown TT, Lee H, Grinspoon SK (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93:3499–3504CrossRefPubMedPubMedCentral

Young B, Dao CN, Buchacz K, Baker R, Brooks JT (2011) Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis 52:1061–1068CrossRefPubMed

Yin MT, Shi Q, Hoover DR et al (2010) Fracture incidence in HIV-infected women: results from the Women’s Interagency HIV Study. AIDS 24:2679–2686CrossRefPubMedPubMedCentral

Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P (2012) Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 26:825–831CrossRefPubMed

Klassen K, Martineau AR, Wilkinson RJ, Cooke G, Courtney AP, Hickson M (2012) The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity. PLoS One 7, e44845CrossRefPubMedPubMedCentral

Mueller NJ, Fux CA, Ledergerber B et al (2010) High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 24:1127–1134CrossRefPubMed

Izzedine H, Harris M, Perazella MA (2009) The nephrotoxic effects of HAART. Nat Rev Nephrol 5:563–573CrossRefPubMed

10.

Kwan CK, Eckhardt B, Baghdadi J, Aberg JA (2012) Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS Res Hum Retroviruses 28:1025–1032PubMed

11.

Bang U, Kolte L, Hitz M, Nielsen SD, Schierbeck LL, Andersen O, Haugaard SB, Mathiesen L, Benfield T, Jensen J-EB (2012) Correlation of increases in 1,25-dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV-1-infected males. HIV Clin Trials 13:162–170CrossRefPubMed

12.

Havens PL, Stephensen CB, Hazra R et al (2012) Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis 54:1013–1025CrossRefPubMedPubMedCentral

13.

Labarga P, Barreiro P, Martin-Carbonero L et al (2010) Prevalence of hyperparathyroidism in HIV-infected patients under antiretrovirals. Antivir Ther 15:A42–A42

14.

Childs KE, Fishman SL, Constable C, Gutierrez JA, Wyatt CM, Dieterich DT, Mullen MP, Branch AD (2010) Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 26:855–859CrossRefPubMedPubMedCentral

15.

Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, Hay PE, Pakianathan MR, Sadiq ST (2010) Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 54:496–499CrossRefPubMed

16.

Masiá M, Padilla S, Robledano C, López N, Ramos JM, Gutiérrez F (2012) Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses 28:242–246CrossRefPubMed

17.

Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084–1093CrossRefPubMed

18.

Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A (2009) Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 49:1591–1601CrossRefPubMed

19.

World Health Organization (2004) WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level

20.

World Health Organization (2004) WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Geneva, Switzerland, p 17 pages

21.

Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, Yalcin AA, Dal K, Yavuz BB, Tutal E (2011) STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther 29:146–152CrossRefPubMed

22.

Ross AC, Manson JE, Abrams SA et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53–58CrossRefPubMedPubMedCentral

23.

Nowson CA, McGrath JJ, Ebeling PR, Haikerwal A, Daly RM, Sanders KM, Seibel MJ, Mason RS (2012) Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust 196:686–687CrossRefPubMed

24.

WHO Consultation on Obesity (1999) Obesity: preventing and managing the global epidemic: report of a WHO consultation. In World Health Organization (ed) WHO technical report series: 894Geneva, Switzerland

25.

Klassen KM, Fairley CK, Kimlin MG, Kelly M, Read TR, Broom J, Russell DB, Ebeling PR (2015) Ultraviolet index and location are important determinants of vitamin D status in people with human immunodeficiency virus (HIV). Photochem Photobiol 91:431–437CrossRefPubMed

26.

Viard JP, Souberbielle JC, Kirk O et al (2011) Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 25:1305–1315CrossRefPubMed

27.

Haskelberg H, Hoy JF, Amin J, Ebeling PR, Emery S, Carr A, Group SS (2012) Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One 7, e38377CrossRef

28.

Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B, Orav JE, Li RF, Spiegelman D, Dietrich T, Willett WC (2009) Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among US adults. J Bone Miner Res 24:935–942CrossRefPubMedPubMedCentral

29.

Bischoff-Ferrari HA, Willett WC, Orav EJ et al (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367:40–49CrossRefPubMed

30.

Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, Shane E, Golub ET, Anastos K (2010) Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 53:202–208CrossRefPubMedPubMedCentral

31.

Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M, Addesso V, Shane E (2005) Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 16:1345–1352CrossRefPubMedPubMedCentral

32.

Havens PL, Kiser JJ, Stephensen CB et al (2013) Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother 57:5619–5628CrossRefPubMedPubMedCentral

33.

Soriano V, Labarga P, Barreiro P et al (2009) Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23:689–696CrossRefPubMed

34.

Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, Hesse K, Hirschel B, Cooper DA, Carr A (2009) Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 200:1746–1754CrossRefPubMed

35.

Gilead Sciences I (2015) Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment http://www.gilead.com/news/press-releases/2015/4/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixeddose-combination-of-emtricitabinetenofovir-alafenamide-for-hiv-treatment Accessed 17 June 2015

36.

Bolland MJ, Grey AB, Gamble GD, Reid IR (2007) CLINICAL review #: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 92:4522–4528CrossRefPubMed

37.

Laitinen J, Kiukaanniemi K, Heikkinen J, Koiranen M, Nieminen P, Sovio U, Keinänen-Kiukaanniemi S, Järvelin MR (2005) Body size from birth to adulthood and bone mineral content and density at 31 years of age: results from the northern Finland 1966 birth cohort study. Osteoporos Int 16:1417–1424CrossRefPubMed

38.

Greco EA, Fornari R, Rossi F et al (2010) Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index. Int J Clin Pract 64:817–820CrossRefPubMed

39.

Stewart KJ, Deregis JR, Turner KL, Bacher AC, Sung J, Hees PS, Tayback M, Ouyang P (2002) Fitness, fatness and activity as predictors of bone mineral density in older persons. J Intern Med 252:381–388CrossRefPubMed

40.

Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW (2007) Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 92:1640–1646CrossRefPubMedPubMedCentral

41.

Prentice A, Goldberg GR, Schoenmakers I (2008) Vitamin D across the lifecycle: physiology and biomarkers. Am J Clin Nutr 88:500S–506SPubMed

42.

Vásquez E, Shaw BA, Gensburg L, Okorodudu D, Corsino L (2013) Racial and ethnic differences in physical activity and bone density: National Health and Nutrition Examination Survey, 2007–2008. Prev Chronic Dis 10, E216CrossRefPubMedPubMedCentral

43.

Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin R, Ribaudo HJ, Yin MT (2014) High-dose vitamin D and calcium attenuates bone loss with ART initiation: results from ACTG A5280. CROI

Title: Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV
Authors: K. M. Klassen
M. G. Kimlin
C. K. Fairley
S. Emery
P. H. Anderson
P. R. Ebeling
on behalf of the STEAL Study Group
Publication date: 01-05-2016
Publisher: Springer London
Published in: Osteoporosis International / Issue 5/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-015-3432-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2016

Multiple clinical vertebral fractures following denosumab discontinuation

Polymorphisms in Wnt signaling pathway genes are associated with peak bone mineral density, lean mass, and fat mass in Chinese male nuclear families

Mechanisms of vasodilation to PTH 1–84, PTH 1–34, and PTHrP 1–34 in rat bone resistance arteries

Cancel the denosumab holiday

Bone matrix mineralization is preserved during early perimenopausal stage in healthy women: a paired biopsy study

Optimal age of commencing and discontinuing thiazide therapy to protect against fractures